110 related articles for article (PubMed ID: 9637487)
1. IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes.
Yeh KY; McAdam AJ; Pulaski BA; Shastri N; Frelinger JG; Lord EM
J Immunol; 1998 Jun; 160(12):5773-80. PubMed ID: 9637487
[TBL] [Abstract][Full Text] [Related]
2. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of class I and class II MHC-restricted antigen presentation by cytotoxic T lymphocytes specific for an exogenous antigen.
Rock KL; Rothstein L; Fleischacker C; Gamble S
J Immunol; 1992 May; 148(10):3028-33. PubMed ID: 1578128
[TBL] [Abstract][Full Text] [Related]
4. Presentation of exogenous antigens by macrophages: analysis of major histocompatibility complex class I and II presentation and regulation by cytokines.
Kovacsovics-Bankowski M; Rock KL
Eur J Immunol; 1994 Oct; 24(10):2421-8. PubMed ID: 7925570
[TBL] [Abstract][Full Text] [Related]
5. IL-3-mediated enhancement of particulate antigen presentation by macrophages.
Lord EM; Yeh KY; Moran JA; Storozynsky E; Frelinger JG
J Immunother; 1998 May; 21(3):205-10. PubMed ID: 9610912
[TBL] [Abstract][Full Text] [Related]
6. MHC class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo.
Grant EP; Rock KL
J Immunol; 1992 Jan; 148(1):13-8. PubMed ID: 1727862
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells.
Svensson M; Stockinger B; Wick MJ
J Immunol; 1997 May; 158(9):4229-36. PubMed ID: 9126984
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells.
Pulaski BA; Yeh KY; Shastri N; Maltby KM; Penney DP; Lord EM; Frelinger JG
Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3669-74. PubMed ID: 8622994
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of MHC class I-restricted T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway.
Martinez-Kinader B; Lipford GB; Wagner H; Heeg K
Immunology; 1995 Oct; 86(2):287-95. PubMed ID: 7490131
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.
Rock KL; Clark K
J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907
[TBL] [Abstract][Full Text] [Related]
11. Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
Svensson M; Pfeifer J; Stockinger B; Wick MJ
Behring Inst Mitt; 1997 Feb; (98):197-211. PubMed ID: 9382741
[TBL] [Abstract][Full Text] [Related]
12. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules.
Rock KL; Rothstein L; Gamble S; Fleischacker C
J Immunol; 1993 Jan; 150(2):438-46. PubMed ID: 8419476
[TBL] [Abstract][Full Text] [Related]
13. Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses.
Ke Y; Li Y; Kapp JA
Eur J Immunol; 1995 Feb; 25(2):549-53. PubMed ID: 7875219
[TBL] [Abstract][Full Text] [Related]
14. Nonionic triblock copolymers facilitate delivery of exogenous proteins into the MHC class I and class II processing pathways.
Ke Y; McGraw CL; Hunter RL; Kapp JA
Cell Immunol; 1997 Mar; 176(2):113-21. PubMed ID: 9073383
[TBL] [Abstract][Full Text] [Related]
15. Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo.
Böhm W; Schirmbeck R; Elbe A; Melber K; Diminky D; Kraal G; van Rooijen N; Barenholz Y; Reimann J
J Immunol; 1995 Oct; 155(7):3313-21. PubMed ID: 7561024
[TBL] [Abstract][Full Text] [Related]
16. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.
Kovacsovics-Bankowski M; Clark K; Benacerraf B; Rock KL
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):4942-6. PubMed ID: 8506338
[TBL] [Abstract][Full Text] [Related]
17. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
18. Ovalbumin-specific, MHC class I-restricted, alpha beta-positive, Tc1 and Tc0 CD8+ T cell clones mediate the in vivo inhibition of rat IgE.
MacAry PA; Holmes BJ; Kemeny DM
J Immunol; 1998 Jan; 160(2):580-7. PubMed ID: 9551891
[TBL] [Abstract][Full Text] [Related]
19. Delivery of exogenous antigen into the major histocompatibility complex class I and class II pathways by electroporation.
Li Y; Ke Y; Gottlieb PD; Kapp JA
J Leukoc Biol; 1994 Nov; 56(5):616-24. PubMed ID: 7525819
[TBL] [Abstract][Full Text] [Related]
20. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells.
Norbury CC; Chambers BJ; Prescott AR; Ljunggren HG; Watts C
Eur J Immunol; 1997 Jan; 27(1):280-8. PubMed ID: 9022030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
